Effect of chloroquine on isolated mast cells.

Chloroquine liberated a relatively low amount of histamine from isolated rat mast cells. In a dose-dependent way, this drug inhibited histamine liberation from mast cells stimulated with compound 48/80, A23187, concanavalin A plus phosphatidylserine (Con A + PS) and abolished histamine liberation induced by exaprolol. The degranulation was decreased in cells stimulated with 48/80, Con A + PS and exaprolol. Chloroquine significantly inhibited the formation of thromboxane B2 in mast cells stimulated with 48/80, Con A + PS and A23187. We assume that chloroquine interferes with mast cells at a plasmic membrane site as well as intracellularly.     

The effect of beta-adrenoceptor blocking drugs on histamine liberation, prostaglandin synthesis and phospholipid turnover in isolated mast cells stimulated with concanavalin A.

Exaprolol, metipranolol and propranolol decreased significantly histamine liberation, degranulation, 45Ca uptake and thromboxane B2 formation in isolated rat mast cells stimulated with concanavalin A and phosphatidylserine. Moreover, exaprolol and metipranolol decreased 32P incorporation into membrane phospholipids and metipranolol and propranolol reduced the liberation of arachidonic acid from membrane phospholipids of stimulated mast cells. Exaprolol significantly increased the arachidonic acid liberation from these cells. Possible mechanisms of interaction of beta-adrenoceptor blocking drugs with isolated mast cells are discussed.     

Membrane perturbing activity of beta-adrenoceptor blocking drugs in isolated rat mast cells

Beta-adrenoceptor blocking (BAB) drugs perturb the membranes of isolated rat mast cells. Membrane fluidisation was temperature dependent and was determined by the liposolubility of the BAB drugs. The secretory index, evaluated as the ratio between histamine liberation and degranulation, correlated with the membrane order parameter of the mast cell membranes. The rank order of potency for mast cell activation and membrane fluidisation was: exaprolol greater than propranolol greater than metipranolol greater than atenolol.     

Atenolol, exaprolol and mast cell membranes.

Lipophilic exaprolol and hydrophilic atenolol differ in their interaction with mast cell membranes. Exaprolol, as compared with atenolol, significantly decreased 32P incorporation into, but increased arachidonic acid liberation from, membrane phospholipids. Moreover, exaprolol significantly decreased phosphate incorporation in compound 48/80 and ConA-PS treated cells and decreased thromboxane formation in stimulated cells. On the other hand, atenolol decreased significantly only arachidonate liberation from stimulated mast cells. These results corroborate to some extent the effect of exaprolol and atenolol on histamine liberation which correlates with their membrane perturbing properties.     

Beta-adrenoceptor blocking drugs and calcium transport in isolated rat mast cells

The beta-adrenoceptor blocking (BAB) drugs exaprolol (EXA), metipranolol (MET) and propranolol (PRO) inhibited histamine liberation and degranulation from isolated rat mast cells stimulated with the calcium ionophore A23187. MET was the most and EXA the least active. Atenolol (ATE) had no effect. Inhibition by BAB drugs of secretion induced with A23187 was not accompanied by any change in 45Ca uptake. On the other hand, EXA, MET and PRO significantly decreased 45Ca uptake by mast cells stimulated with 48/80. The effect of BAB drugs on inhibition of A23187-induced secretion from isolated mast cells was dependent on the lipid solubility of the studied drugs.     

Effect of beta-adrenoceptor blocking drugs on 32P incorporation into and arachidonic acid liberation from phospholipids in stimulated rat mast cells

The lipophilic beta-adrenoceptor blocking (BAB) drugs metipranolol, propranolol and exaprolol significantly decreased 48/80- and A23187-induced 32P incorporation into rat mast cell phospholipids. Exaprolol was the most active, followed by propranolol and metipranolol. Atenolol and metipranolol significantly decreased the 48/80-stimulated, and metipranolol and exaprolol the A23187-stimulated 3H-arachidonic acid liberation from isolated mast cells.     

Histamine liberation as a result of nonreceptor interaction.

The highly lipophilic drug exaprolol liberates histamine from isolated mast cells and decreases the uptake of extracellular histamine in a dose-dependent manner. Intracellular histamine depletion was confirmed by electron microscopy and was accompanied by calcium displacement from intracellular storage sites. The significant decrease in membrane fluidity due to exaprolol was temperature-dependent and was most probably a result of its high membrane affinity and intracellular penetration. Membrane perturbation by exaprolol may account for this nonreceptor interaction. This could contribute to the understanding of adverse reactions to beta-adrenoceptor blocking drugs.     

Analysis of the adverse effects of drugs at the cellular and subcellular levels]

A release of histamine after the lipophilic betablockers exaprolol and propranolol correlates with their capability of displacing the bound membrane Ca2+ and increasing the disorder of phospholipidic membranes of the isolated mast cells. Electron microscopy confirmed intracellular displacement of histamine from granules of mast cells after exaprolol without marked structural changes on the plasmatic membrane. Hydrophilic and selective atenolol, which does not possess a histamine-liberating effect, decreases spontaneous transfer of the intracellular calcium, decreases the disorder of the mast-cell membranes, and together with exaprolol and propranolol inhibits, in dose-dependence way, the gain of extracellular histamine in cells. The inhibitory effect of EDTA, tetrodotoxine and suramine on histamine release after exaprolol explains the non-receptor mechanism of exaprolol effect, which confirms a possibility of induction of adverse effects of blockers of the beta-adrenergic receptor in the development of a bronchospasm.     

Effect of stobadine on stimulated isolated mast cells

Stobadine, an antiarrhythmic drug with antihistaminic properties, did not liberate histamine from mast cells in vitro. Compound 48/80-stimulated histamine liberation and degranulation was decreased in the presence of stobadine in a dose-dependent way. The spontaneous as well as stimulated calcium displacement in mast cells was significantly decreased by stobadine. Stobadine most probably possesses a membrane-stabilizing effect on isolated rat mast cells.     

On the interaction of beta-adrenoceptor-blocking drugs with isolated mast cells

The interaction of beta-adrenoceptor blocking drugs (BAB drugs) with isolated mast cells resulted, according to the compound, in either a liberation of biogenic amines or an inhibition of stimulated amine release. The liberatory drugs exaprolol and K? 1124 decreased the level of cAMP, stimulated the activity of cyclic nucleotide-phosphodiesterase, decreased the incorporation of orthophosphate into membrane phospholipids and rapidly displaced calcium from binding sites in mast cells. The inhibitory drugs alprenolol, metipranolol, oxprenolol, practolol and propranolol, possessing lower liposolubility, produced opposite effects. Drugs from both groups displaced histamine from binding sites in isolated mast cell granules. The interaction of BAB drugs with mast cells is a result of non-specific rather than specific receptor interactions. Inhibitory drugs interfere with mast cells at membrane sites while liberatory drugs penetrate the membrane, thus acting both at the level of membrane and intracellularly.     

Amine transport in isolated rat mast cells treated with betaadrenoceptor blocking drugs

Histamine and serotonin uptake in isolated rat mast cells is decreased in the presence of betaadrenoceptor blocking (BAB) drugs. Such inhibition is dose-dependent and is evidently higher for the inhibition of serotonin uptake. The most potent drugs were the highly lipophilic compounds K? 1124 and propranolol. No difference was found among the various BAB drugs in their ability to decrease histamine uptake. It is evident from the ratio between histamine and serotonin liberation on one side, to the uptake of both amines in mast cells on the other side, that with the exception of K? 1124, all investigated BAB drugs possesses higher inhibition of extracellular amine uptake in comparison with histamine and serotonin liberation. Such an effect might be a result of a primary interaction of BAB drugs with mast cells at the plasma membrane.     

Histamine liberation and membrane fluidisation of mast cells exposed to the beta-adrenoceptor blocking drug propranolol

Propranolol liberates histamine from isolated mast cells and decreases the uptake of extracellular histamine in a dose-dependent way. Histamine liberation due to propranolol is accompanied by calcium displacement from intracellular storage sites. The significant increase in membrane fluidity due to propranolol is temperature dependent. The perturbation of membranes is most probably the explanation of propranolol's interaction with isolated rat mast cells which results in altered histamine transportation.     

On the interaction of local anesthetics with mast cells

The carbanilate local anesthetics carbisocaine, hepatacaine and pentacaine liberate histamine from isolated rat mast cells. Procaine, carticaine, trimecaine, cocaine and butanilicaine were ineffective. Histamine liberation was dose-dependent, followed by calcium displacement from membrane binding sites and occurred without concomitant degranulation. Low temperature and pH-dependent inhibition of histamine liberation indicated a non-specific, membrane perturbing effect of highly liposoluble carbanilate local anesthetics. Conformational changes in the sodium channel on the mast cell membrane induced by carbanilate anesthetics might result in histamine exchange occurring intracellularly.     

The effect of beta-adrenergic blocking drugs and inhibitors of phosphodiestease on histamine release from isolated mast cells.

Differences in the histamine liberation from isolated rat mast cells after beta-adrenergic blocking drugs were demonstrated. In equimolar concentrations histamine release was induced by K? 1124, K? 1500, K? 1560, K? 1561 and propranolol. Alprenolol, oxprenolol, propranolol, and trimepranol significantly decreased thehistamine release induced by compound 48-80. The release of granules from cells was inhibited quantitatively more than the release of histamine. This enabled us to surmise the selective effect of beta-adrenergic blocking drugs on cell membranes of mast cells. The possible mechanisms of release reaction are discussed.     

On the relationship between incorporation of 32P into phospholipids and binding of beta-adrenoceptor blocking drugs to isolated mast cells

The lipophilic beta-adrenoceptor blocking drugs exaprolol and propranolol significantly decreased the incorporation of 32P into phosphatidylethanolamine, phosphatidylcholine and phosphatidylinositol of isolated rat mast cells. In contrast, the hydrophilic drugs metipranolol, practolol and atenolol increased the incorporation of 32P into phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol. The inhibition of 32P incorporation by lipophilic drugs correlated with the high binding of these drugs to mast cells.     

Inhibition of histamine release from human lung in vitro by antihistamines and related drugs.

1 A series of cationic, lipophilic histamine H1-receptor antagonists, neuroleptics, antidepressants and monoamine oxidase inhibitors were tested for their effects on anti-IgE-induced histamine release from human lung fragments in vitro. 2 They had a biphasic effect: at low concentrations a dose-related inhibition of histamine release was observed whereas, at higher concentrations, the drugs liberated histamine even in the absence of antigen. 3 Mepyramine, a much less lipophilic drug than the others tested, was only weakly active on mast cells at pharmacological concentrations. 4 The potency of the drugs as release inhibitors was not related quantitatively to their histamine liberating potency. 5 There was no; correlation between activity on mast cells and histamine H1-receptor antagonism. 6 Mast cell stabilization may play a part in the activity of these drugs as anti-allergic agents.     

Effects of human recombinant IL-1 on d-tubocurarine-induced histamine release from isolated rat peritoneal mast cells.

The relationship between d-tubocurarine (d-Tc) and human recombinant interleukin-1 (rIL-1) was studied on the histamine-releasing property of isolated rat peritoneal mast cells. d-Tc induced histamine release in a dose-dependent manner (1 x 10(-4) M-3 x 10(-3) M) from isolated rat mast cells. Human rIL-1 (0.3-10 ng/ml) potentiated the d-Tc-induced histamine release and shifted the dose-response curve to left without changing the maximum histamine release by d-Tc. The potentiation by human rIL-1 was completely blocked by anti-IL-1-antibody. Human rIL-1 neither released histamine nor affected IgE-related histamine release in isolated rat peritoneal mast cells. Human recombinant IL-2, IL-3, and tumour necrosis factor neither released histamine from isolated rat mast cells nor affected d-Tc-induced histamine release. These results suggested that human rIL-1 might hypersensitize d-Tc receptors distributed on plasma membrane of rat mast cells.     

The role of membrane bound sialic acid of rat mast cells in histamine release induced by compound 48/80 and derivatives as well as calcium

Histamine release induced by compound 48/80 from rat mast cells is not dependent on extracellular Ca2+. Preincubation of mast cells with trypsin has only little effects on histamine release induced by this polycation. This work also demonstrates that histamine release induced by compound 48/80 and its analogues in the absence of extracellular Ca2+ depends on membrane bound sialic acid of the mast cell. Neuraminidase treatment of the cells in the presence of extracellular Ca2+ leads to histamine liberation. These findings suggest that sialic acid residues of the mast cell membrane constitute the site at which polycations exert their stimulatory actions of histamine liberation.     

Some studies on the release of histamine from mast cells treated with d-tubocurarine

d-Tubocurarine (dTc) released histamine in non-cytotoxic fashion from peritoneal mast cells of the rat, mouse and hamster. The response was similar to that evoked by other cationic liberators such as compound 48/80 and polylysine in that it was extremely rapid and enhanced by calcium-deprivation at suboptimal concentrations of secretagogue. Tissue mast cells obtained by enzymic dissociation of the heart, lung and mesentery of the rat and guinea pig were unreactive or hyporesponsive to the effect of dTc. The compound liberated only very small amounts of histamine from isolated preparations of perfused guinea pig heart but significantly increased the rate and contractility of the heart. These results are discussed in terms of the general functional heterogeneity of mast cells from different locations.     

Increased levels of histamine observed in the skin of adrenaline-treated rats or mice are not the result of histamine synthesis by mast cells

Like the skin of rats and mice injected with adrenaline (AD), rat isolated peritoneal mast cells display increased levels of perchloric acid-soluble histamine following incubation with AD. Although pre-exposure to alpha-fluoromethyl histidine (FMH), an inhibitor of histidine decarboxylase, prevented the effect of AD in vivo and in vitro, this compound was also found to inhibit mast cell granule swelling evoked by AD, a response linked to histamine changes. Absence of increased levels of isotopic histamine in mast cells incubated with labelled histidine in the presence of AD, as well as the insufficient amounts of would-be precursor histidine found in untreated mast cells, confirm the conclusion that AD does not increase mast cell histamine by stimulating its synthesis.